Defibrotide blunts the prothrombotic effect of thalidomide on endothelial cells.

about

Defibrotide: a review of its use in severe hepatic veno-occlusive disease following haematopoietic stem cell transplantation.

P2860

Q34445293-74D6A74C-04B8-4616-9B27-720A7500512E

P2860

Defibrotide blunts the prothrombotic effect of thalidomide on endothelial cells.

Item

http://www.wikidata.org/entity/Q39511703

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Defibrotide blunts the prothrombotic effect of thalidomide on endothelial cells.

@en

Defibrotide blunts the prothrombotic effect of thalidomide on endothelial cells.

@nl

type

Item

label

Defibrotide blunts the prothrombotic effect of thalidomide on endothelial cells.

@en

Defibrotide blunts the prothrombotic effect of thalidomide on endothelial cells.

@nl

prefLabel

Defibrotide blunts the prothrombotic effect of thalidomide on endothelial cells.

@en

Defibrotide blunts the prothrombotic effect of thalidomide on endothelial cells.

@nl

P1476

Defibrotide blunts the prothrombotic effect of thalidomide on endothelial cells.

@en

P2093

A Palumbo

http://www.w3.org/2001/XMLSchema#string

C L Echart

http://www.w3.org/2001/XMLSchema#string

J Fareed

http://www.w3.org/2001/XMLSchema#string

M Distaso

http://www.w3.org/2001/XMLSchema#string

M Iacobelli

http://www.w3.org/2001/XMLSchema#string

P G Richardson

http://www.w3.org/2001/XMLSchema#string

S Somaini

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2008

Arterial thrombosis in four patients treated with thalidomide

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial.

Hepatic veno-occlusive disease following hematopoietic stem cell transplantation.

Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias

Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide.

From the bench to the bedside: emerging new treatments in multiple myeloma.

Advances in treatment for relapses and refractory multiple myeloma.

Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders.

HMEC-1: establishment of an immortalized human microvascular endothelial cell line.

P304

79-86

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1076029611412367

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21733935

http://www.w3.org/2001/XMLSchema#string

P921

endothelium

thalidomide

Defibrotide blunts the prothrombotic effect of thalidomide on endothelial cells.

about

P2860

P2860

Defibrotide blunts the prothrombotic effect of thalidomide on endothelial cells.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921